

Research Roundtable of the Alzheimer's Association Record of Publications

Tau biology, biomarkers, and therapeutics. Frost B, Kolb H, Algeciras-Schimmich A, Betthausen TJ, DeVos S, Edelmayer RM, Elwood F, Fleisher AS, Henley D, Horie K, Hyman B, Kreisl WC, Kulic L, Leuzy A, Palma JA, Parmentier-Batteur S, Patru MM, Rabinovici GD, Reyderman L, Sperling RA, Van Der Geyten S, Wildsmith KR, Mahinrad S, Carrillo MC, Weber CJ. *Alzheimers Dement* (N Y). 2025 Oct 21;11(4):e70165. doi: 10.1002/trc2.70165. PMID: 41126950; PMCID: PMC12538647.

System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment. Snider BJ, Biffi A, Bozeat S, Clevenger C, Farrar G, Gitelman D, Kolster R, Mattke S, Mielke M, Mukherjee D, Murphy J, Okhravi H, Rabinovici GD, Rentz D, Soria J, Synder H, Walker G, Mahinrad S, Carrillo MC, Weber CJ. *Alzheimers Dement* (N Y). 2025 Jun 19;11(2):e70094. doi: 10.1002/trc2.70094. PMID: 40547330; PMCID: PMC12178942.

Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease. Petersen, R. C., Graf, A., Atkins, A. S., Brys, M., Murphy, J., Miller, D. S., Reyderman, L., Siemers, E., Smith, J., Carrillo, M. C., & Weber, C. J. (2025). *Alzheimer's & dementia* (New York, N. Y.), 11(2), e70069. <https://doi.org/10.1002/trc2.70069>

Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable. Farrar G, Weber CJ, Rabinovici GD. *J Prev Alzheimers Dis*. 2025 Jan;12(1):100008. doi: 10.1016/j.tjpad.2024.100008. Epub 2025 Jan 1. PMID: 39800462.

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting. Petersen, R. C., Graf, A., Brady, C., De Santi, S., Florian, H., Landen, J., Pontecorvo, M., Randolph, C., Sink, K., Carrillo, M., & Weber, C. J. (2025). *Alzheimer's & dementia* (New York, N. Y.), 11(1), e70038. <https://doi.org/10.1002/trc2.70038>

Application of Revised ATN Classification: Drug Development & Clinical Practice. Jack, C. R., Graf, A., Burnham, S. C., Doty, E. G., Moebius, H. J., Montenegro, P., Siemers, E., Sink, K. M., Shaw, L. M., Hansen, C. T., Wildsmith, K. R., Mahinrad, S., Carrillo, M. C., & Weber, C. J. (2024). *Alzheimer's & dementia* (New York, N. Y.), 10(4), e70013. <https://doi.org/10.1002/trc2.70013>

Alzheimer's disease drug development in an evolving therapeutic landscape. Weninger, S., Irizarry, M. C., Fleisher, A. S., León, T., Maruff, P., Miller, D. S., Seleri, S., Carrillo, M. C., & Weber, C. J. (2024). *Alzheimer's & dementia* (New York, N. Y.), 10(4), e70015. <https://doi.org/10.1002/trc2.70015>

Understanding recent advances in non-amyloid/non-tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease. Van Eldik, L. J., Siemers, E. R., Collins, E. C., Gold, M., Henley, D., Johannsen, P., Möbius, H. J., Shulman, M., Zhou, J., Carrillo, M., & Weber, C. (2024). *Alzheimer's & dementia* (New York, N. Y.), 10(4), e70014. <https://doi.org/10.1002/trc2.70014>

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations.

Petersen RC, Graf A, Brady C, De Santi S, Florian H, Landen J, Pontecorvo M, Randolph C, Sink KM, Carrillo MC, Weber CJ. *Alzheimers Dement* (N Y). 2023 Nov 17;9(4):e12434. doi: 10.1002/trc2.12434. PMID: 38023620; PMCID: PMC10655199.

Decision making in clinical trials: Interim analyses, innovative design, and biomarkers.

Welsh-Bohmer KA, Kerchner GA, Dhadda S, Garcia M, Miller DS, Natanegara F, Raket LL, Robieson W, Siemers ER, Carrillo MC, Weber CJ. *Alzheimers Dement* (N Y). 2023 Oct 18;9(4):e12421. doi: 10.1002/trc2.12421. PMID: 37867532; PMCID: PMC10585126.

Current understanding of AD pathophysiology and impact of amyloid beta-targeted treatments on biomarkers and clinical endpoints. Petersen RC, Graf A, Carrillo MC, Weber CJ. *Alzheimers Dement*. 2022 Aug;18(8):1586. doi: 10.1002/alz.12769. Epub 2022 Aug 10. PMID: 35946224.

Building clinically relevant outcomes across the Alzheimer's disease spectrum.

Rentz DM, Wessels AM, Annapragada AV, Berger AK, Edgar CJ, Gold M, Miller DS, Randolph C, Ryan JM, Wunderlich G, Zoschg MC, Trépel D, Knopman DS, Staffaroni AM, Bain LJ, Carrillo MC, Weber CJ. *Alzheimers Dement* (N Y). 2021 Jun 26;7(1):e12181. doi: 10.1002/trc2.12181. PMID: 34195350; PMCID: PMC8234696.

Active Immunotherapy and Alternative Therapeutic Modalities for Alzheimer's Disease

Weninger S, Sperling B, Alexander R, Ivarsson M, Menzies FM, Powchik P, Weber CJ, Altar CA, Crystal RG, Haggarty SJ, Loring J, Bain LJ, Carrillo MC. Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease. *Alzheimers Dement* (N Y). 2020 Oct 12;6(1):e12090. doi: 10.1002/trc2.12090. PMID: 33083513; PMCID: PMC7550557.

Preclinical Alzheimer's Disease and the Pathway to Prevention: The Alzheimer's Association Research Roundtable

McDade E, Bednar MM, Brashear HR, Miller DS, Maruff P, Randolph C, Ismail Z, Carrillo MC, Weber CJ, Bain LJ, Hake AM. The pathway to secondary prevention of Alzheimer's disease. *Alzheimers Dement* (N Y). 2020 Aug 27;6(1):e12069. doi: 10.1002/trc2.12069. PMID: 32885024; PMCID: PMC7453146.

Advancing Combination Therapy for Alzheimer's Disease

Salloway SP, Sevingy J, Budur K, Pederson JT, DeMattos RB, Von Rosenstiel P, Paez A, Evans R, Weber CJ, Hendrix JA, Worley S, Bain LJ, Carrillo MC. Advancing combination therapy for Alzheimer's disease. *Alzheimers Dement* (N Y). 2020 Oct 7;6(1):e12073. doi: 10.1002/trc2.12073. PMID: 33043108; PMCID: PMC7539671.

The NIA-AA Research Framework for Alzheimer's Disease: Perspectives from the Research Roundtable

Gold M, Amatniek J, Carrillo MC, Cedarbaum JM, Hendrix JA, Miller BB, Robillard JM, Rice JJ, Soares H, Tome MB, Tarnanas I, Vargas G, Bain LJ, Czaja SJ. Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials. *Alzheimers Dement* (N Y). 2018 May 24;4:234-242. doi: 10.1016/j.trci.2018.04.003. PMID: 29955666; PMCID: PMC6021547.

Digital Technologies as Biomarkers, Clinical Outcomes Assessment and Recruitment Tools in Alzheimer's Disease Clinical Trials

Michael Gold, Joan Amatniek, Maria C. Carrillo, Jesse M. Cedarbaum, James A. Hendrix, Bradley B. Miller, Julie M. Robillard, J. Jeremy Rice, Holly Soares, Maria B. Tome, Ioannis Tarnanas, Gabriel Vargas, Lisa J. Bain, Sara J. Czaja *Alzheimer's & Dementia: Translational Research & Clinical Interventions* **2018**, 4, 234–242.

Measuring Cognition and Function in the Preclinical Stage of Alzheimer's Disease

Weintraub, S.; Carrillo, M.C.; Tomaszewski Farias, S.; Goldberg, T.E.; Hendrix, J.A.; Jaeger, J.; Knopman, D.S.; Langbaum, J.B.; Park, D.C.; Ropacki, M.T.; Sikkes, S.A.M.; Welsh-Bohmer, K.A.; Bain, L.J.; Brashear, R.; Budur, K.; Graf, A.; Martenyi, F.; Segardahl Storck, M.; Randolph C. *Alzheimer's & Dementia: Translational Research & Clinical Interventions* **2018**, 4, 64–75.

National Institute on Aging – Alzheimer's Association Research Framework Lays the Groundwork for Deeper Understanding of Alzheimer's disease

Knopman, D.S.; Siemers, E.R.; Bain, L.J.; Hendrix, J.A.; Carrillo, M.C. *Alzheimer's & Dementia* **2018**, 14 (2), 261–262.

Neuropsychiatric Signs and Symptoms of Alzheimer's Disease: New Treatment Paradigms

Lancôt, K.L.; Amatniek, J.; Ancoli-Israel, S.; Arnold, S.E.; Ballard, C.; Cohen-Mansfield, J.; Ismail, Z.; Lyketsos, C.; Miller, D.S.; Musiek, E.; Osorio, R.S.; Rosenberg, P.B.; Satlin, A.; Steffens, D.; Tariot, P.; Bain, L.J.; Carrillo, M.C.; Hendrix, J.A.; Jurgens, H.; Boot, B. *Alzheimer's & Dementia: Translational Research & Clinical Interventions* **2017**, 3, 440–449.

Tau: From research to clinical development

Holtzman DM, Carrillo MC, Hendrix JA, Bain LJ, Catafau AM, Gault LM, Goedert M, Mandelkow E, Mandelkow EM, Miller DS, Ostrowitzki S, Polydoro M, Smith S, Wittmann M, Hutton M. Tau: From research to clinical development. *Alzheimers Dement*. 2016 Oct;12(10):1033-1039. doi: 10.1016/j.jalz.2016.03.018. Epub **2016** May 4. PMID: 27154059.

The Roles of Inflammation and Immune Mechanisms in Alzheimer's Disease

Linda J. Van Eldik, Maria Carrillo, Patricia E. Cole, Dominik Feuerbach, Barry D. Greenberg, James Hendrix, Matthew Kennedy, Nick Kozauer, Richard A. Margolin, José L. Molinuevo, Reinhold Mueller, Richard M. Ransohoff, Donna M. Wilcock, Lisa Bain, Kelly Bales *Alzheimer's & Dementia: Translational Research & Clinical Interventions* **2016**, 2 (2), 99–109.

Additional/Co-morbid Neuropathologies in the setting of Alzheimer's Disease

Neuropathology: Impact on Drug Development

Gil D. Rabinovici, Maria C. Carrillo, Mark Forman, Susan DeSanti, David S. Miller, Nicholas Kozauer, Ronald C. Petersen, Christopher Randolph, David S. Knopman, Eric E. Smith, Maria Isaac, Niklas Mattsson, Lisa J. Bain, James A. Hendrix, John R. Sims, *Alzheimer's & Dementia: Translational Research & Clinical Interventions* published on-line Sept. 20, **2016**, <http://dx.doi.org/10.1016/j.trci.2016.09.002>.

Challenges, Solutions and Consensus Recommendations for Alzheimer's Disease

Combination Therapy

Hendrix JA, Bateman RJ, Brashear HR, Duggan C, Carrillo MC, Bain LJ, DeMattos R, Katz RG, Ostrowitzki S, Siemers E, Sperling R, Vitolo OV. Challenges, solutions, and recommendations for Alzheimer's disease combination therapy. *Alzheimers Dement*. **2016** May;12(5):623-30. doi: 10.1016/j.jalz.2016.02.007. Epub 2016 Mar 24. PMID: 27017906.

Considerations for the assessment of suicidal ideation and behavior in older adults with cognitive decline and dementia

Alphs L, Brashear HR, Chappell P, Conwell Y, Dubrava S, Khin NA, Kozauer N, Hartley DM, Miller DS, Schindler RJ, Siemers ER, Stewart M, Yaffe K. Considerations for the assessment of suicidal ideation and behavior in older adults with cognitive decline and dementia. *Alzheimers Dement* (N Y). **2016** Feb 23;2(1):48-59. doi: 10.1016/j.trci.2016.02.001. PMID: 29067293; PMCID: PMC5644272.

Revolution of Alzheimer's Disease Understanding and Trials Through Biomarkers

Mattsson N, Carrillo MC, Dean RA, Devous MD Sr, Nikolcheva T, Pesini P, Salter H, Potter WZ, Sperling RS, Bateman RJ, Bain LJ, Liu E. Revolutionizing Alzheimer's disease and clinical trials through biomarkers. *Alzheimers Dement* (Amst). **2015** Oct 3;1(4):412-9. doi: 10.1016/j.dadm.2015.09.001. PMID: 27239522; PMCID: PMC4879481.

Assessing Cognition and Function in Alzheimer's Disease Clinical Trials: Do We Have the Right Tools?

Snyder PJ, Kahle-Wroblewski K, Brannan S, Miller DS, Schindler RJ, DeSanti S, Ryan JM, Morrison G, Grundman M, Chandler J, Caselli RJ, Isaac M, Bain L, Carrillo MC. Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools? *Alzheimers Dement*. **2014** Nov;10(6):853-60. doi: 10.1016/j.jalz.2014.07.158. Epub 2014 Nov 15. PMID: 25458309.

Justifying Reimbursement for Alzheimer's Diagnostics and Treatments: Seeking Alignment on Evidence

Foster NL, Hackett JSM, White G, Chenevert S, Svarvar P, Bain L, Carrillo MC. Justifying reimbursement for Alzheimer's diagnostics and treatments: Seeking alignment on evidence. *Alzheimers Dement*. **2014** Jul;10(4):503-508. doi: 10.1016/j.jalz.2014.05.003. PMID: 24985689.

Revisiting the Framework of the National Institute on Aging-Alzheimer's Association Diagnostic Criteria, October 2012

Carrillo MC, Dean RA, Nicolas F, Miller DS, Berman R, Khachaturian Z, Bain LJ, Schindler R, Knopman D; Alzheimer's Association Research Roundtable. Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria. *Alzheimers Dement*. **2013** Sep;9(5):594-601. doi: 10.1016/j.jalz.2013.05.1762. PMID: 24007744.

Let's Get Real About Non-Amyloid Targets in Alzheimer's Disease, April 2012

Herrup K, Carrillo MC, Schenk D, Cacace A, Desanti S, Fremeau R, Bhat R, Glicksman M, May P, Swerdlow R, Van Eldik LJ, Bain LJ, Budd S. Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease. *Alzheimer's & Dementia*, **2013**; 9; 452-458.

Prevention Trials in Alzheimer's Disease, October 2011

Carrillo MC, Brashear HR, Logovinsky V, Ryan JM, Feldman HH, Siemers ER, Abushakra S, Petersen RC, Khachaturian AS, Sperling RA: Can we prevent AD? Secondary "Prevention" Trials in Alzheimer's Disease. *Alzheimer's & Dementia*, **2013**; 9; 123-131.

Phase II Clinical Trials in Alzheimer's Disease, June 2011

Greenberg, BD, Carrillo, MC, Ryan, MJ, Gold, M, Gallagher, K, Grundman, M, Berman, RM, Ashwood, T, Siemers, ER. Improving Alzheimer's Disease Phase II Clinical Trials. *Alzheimer's & Dementia* **2013**; 9; 39-49.

Epidemiology of Alzheimer's Disease, October 2010

Yaffe, K, Tocco, M, Petersen, RC, Sigler, C, Burns, LC, Cornelius, C, Khachaturian, A, Irizarry, MC, Carrillo, MC. The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct and analysis of clinical trials. *Alzheimer's & Dementia* **2012**; 8; 237-42.

VE Expert Working Group Meeting, October 2010

Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. *Alzheimers Dement*. **2011** Jul;7(4):367-85. doi: 10.1016/j.jalz.2011.05.2351. PMID: 21784348; PMCID: PMC3693547.

Challenges in NPS in Alzheimer's Disease, April 2010

Lyketsos, CG, Carrillo, MC, Ryan, JM, Khachaturian, AS, Trzepacz, P, Amatniek, J, Cedarbaum, J, Brashear, R, Miller, DS. Neuropsychiatric Symptoms in Alzheimer's disease. *Alzheimer's & Dementia* **2011**;7:532-539.

Global Clinical Trials in Alzheimer's Drug Development Meeting, November 2009

Doody, RS, Cole, PE, Miller, DS, Siemers, ER, Black, R, Feldman, H, Schindler, R, Graham, S, Heath, T, Khachaturian, AS, Evans, R, Carrillo, MC. Global issues in drug development for Alzheimer's disease. *Alzheimer's & Dementia*. **2011**; 7:197-207.

Alzheimer's Disease Classification Meeting, April 2009

DeKosky, ST, Carrillo, MC, Phelps, C, Knopman, D, Petersen, RC, Frank, R, Schenk, D, Masterman, D, Siemers, ER, Cedarbaum, JM, Gold, M, Miller, DS, Morimoto, BH, Khachaturian, AS, Mohs, RC. Revision of the criteria for Alzheimer's disease: A symposium. *Alzheimer's & Dementia* **2011**; 7:e1-e12.

Optimal Trial Design for Alzheimer's Drug Discovery Meeting, November 2008

Not published

Scales for Alzheimer's Disease Meeting, April 2008

Black, R, Greenberg, B, Ryan, JM, Posner, H, Seeburger, J, Amatniak, J, Resnick, M, Mohs, R, Miller, DS, Saumnier, D, Carrillo, MC, Stern, Y. Scales as Outcome Measures for Alzheimer's Disease. *Alzheimer's & Dementia* **2009**; 5:324-339.

Early Risk Assessment for Alzheimer's Disease Meeting, November 2007

Carrillo, MC, Blackwell, A, Hampel, H, Lindborg, J, Sperling, R, Schenk, D, Sevigny, JJ, Ferris, S, Bennett, DA, Craft, S, Hsu, T, Klunk, W. Perspective: Early Risk Assessment for Alzheimer's Disease. *Alzheimer's & Dementia* **2009**; 5:182-196.

Academic/Industry Interface for Alzheimer's Drug Discovery Meeting, April 2007

Ivinson, A.J., Lane, R., May, P.C., Hosford, D.A., Carrillo, M.C. & Siemers, E.R. Perspective: The academic/industry interface for Alzheimer's drug discovery. *Alzheimer's & Dementia* **2008**; 4: 80-88.

Health Economics & Real World Value of AD Therapy Meeting, November 2006:

Perspective: Health Economics and Value of Therapy in Alzheimer's Disease. Schwam, E.M., Abu-Shakra, S., del Valle, M., Townsend, R.J., Carrillo, M.C. & Fillit, H. *Alzheimer's & Dementia* **2007**;3:143-151.

Wimo A, Norlund A. Commentary on "Health economics and the value of therapy in Alzheimer's disease." Cost-effectiveness studies. *Alzheimers Dement*. **2007** Jul;3(3):157-61. doi: 10.1016/j.jalz.2007.04.390. PMID: 19595931.

Ready RE. Commentary on "Health economics and the value of therapy in Alzheimer's disease." Patient-reported outcomes in clinical trials for Alzheimer's disease. *Alzheimers Dement*. **2007** Jul;3(3):172-6. doi: 10.1016/j.jalz.2007.04.385. PMID: 19595934.

Vellas B, Froelich L, Sampaio C. Commentary on "Health economics and the value of therapy in Alzheimer's disease." Value therapy for Alzheimer's disease--a European perspective. *Alzheimers Dement*. **2007** Jul;3(3):152-6. doi: 10.1016/j.jalz.2007.04.382. PMID: 19595930.

Cohen JT, Neumann PJ. Decision analytic models for Alzheimer's disease: state of the art and future directions. *Alzheimers Dement*. **2008** May;4(3):212-22. doi: 10.1016/j.jalz.2008.02.003. PMID: 18631970.

Banerjee S. Commentary on "Health economics and the value of therapy in Alzheimer's disease." Quality of life in dementia: development and use of a disease-specific measure of health-related quality of life in dementia. *Alzheimers Dement*. **2007** Jul;3(3):166-71. doi: 10.1016/j.jalz.2007.04.384. PMID: 19595933.

Jones R. Commentary on "Health economics and the value of therapy in Alzheimer's disease." Drug treatment of Alzheimer's disease: The United Kingdom experience--National Institute for Health and Clinical Excellence guidance and guidelines for dementia. *Alzheimers Dement*. **2007** Jul;3(3):180-5. doi: 10.1016/j.jalz.2007.04.386. PMID: 19595936.

Lancôtôt KL, Herrmann N. Commentary on "Health economics and the value of therapy in Alzheimer's disease." Cholinesterase inhibitors in Alzheimer's disease--evidence-based or evidence-biased? *Alzheimers Dement*. 2007 Jul;3(3):177-9. doi: 10.1016/j.jalz.2007.04.389. PMID: 19595935.

Cytoskeletal Meeting, April 2006:

Perspective: Cytoskeletal Modulators and Pleiotropic Strategies for Alzheimer Drug Discovery. Schenk, D., Carrillo, M.C., & Trojanowski, J.Q. *Alzheimer's & Dementia* 2006;2:275-281.

Lipitor's effect in Alzheimer's dementia (LEADe) Study. Hey-Hadavi, J., *Alzheimer's & Dementia* (2006).

The last stand: The dichotomy of chaperone function in Alzheimer's disease. Dickey, C.A. & Petrucelli, L. *Alzheimer's & Dementia* (2006).

Dietary energy intake and the pathogenesis of Alzheimer's disease. Mattson, M.P. *Alzheimer's & Dementia* (2006).

Pleiotropic Approaches to Alzheimer's and Other Diseases of Aging. Cole, G., & Frautschy, S.A. *Alzheimer's & Dementia* (2006).

Optimal Trial Design Meeting, November 2005:

Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease. Mohs, R.C., Kawas, C., Carrillo, M.C. *Alzheimer's & Dementia* 2006;2:131-139.

Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease". Siemers, E.R. *Alzheimer's & Dementia* (2006).

Disease modification in multiple sclerosis: Issues with relevance to clinical trial designs in Alzheimer's disease. Rudick, R.A. *Alzheimer's & Dementia* (2006).

Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying. Knopman, D. *Alzheimer's & Dementia* (2006).

Disease-modifying treatments for Alzheimer's disease: A perspective based on experience with R-Flubiprofen. Wilcock, G.K. *Alzheimer's & Dementia* (2006).

Development of a disease-modifying treatment for Alzheimer's disease: Alzhemed. Aisen, P.S., *Alzheimer's & Dementia* (2006).

Lessons from osteoporosis clinical trials. Silverman, S.L. *Alzheimer's & Dementia* (2006).
Policy statement on voting by persons with dementia residing in long-term care facilities. Karlawish, J., Appelbaum, P.S., Bonnie, R., Karlan, P., & McConnell, S. *Alzheimer's & Dementia* (2006).

Perspectives on assessing benefits and risks in clinical trials for Alzheimer's disease. McConnell, S., Karlawish, J., Vellas, B., & DeKosky, S. *Alzheimer's & Dementia* (2006).

Biomarkers Meeting, April 2005:

Role of biomarkers in studies of presymptomatic Alzheimer's disease. Morris, J.C., Quaid K., K.A., Holtzman, D.M., Kantarci, K., Kaye, J., Reiman, E.M., Klunk, W.E., & Siemers, E.R. *Alzheimer's & Dementia* (2005).

The role of biomarkers in clinical trials for Alzheimer's disease. Thal, L.J., Kantarci, K., Reiman, E.M., Klunk, W.E., Weiner, M.W., Zetterberg, H., Galasko, D., Pratico, D., Griffin, S., Schenk, D., Siemers, E. *Alzheimer's Disease & Associated Disorders* (2006).

MCI Meeting, September 2004:

Alzheimer Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned? Grundman, M., Petersen, R.C., Bennett, D., Feldman, H., Salloway, S., Jelle Visser, P., Thal, L.J., Schenk, D., Khachaturian, Z., & Thies, W. *Alzheimer's & Dementia* (2006).